The burden of psoriatic arthritis: A literature review from a global health systems perspective

P and T

Volumn 35, Issue 12, 2010, Pages 680-689

  Lee, Seina ^a   Mendelsohn, Alan ^b   Sarnes, Evelyn ^c  

^a Worldwide Market Access   (United States)

^b Centocor Ortho Biotech Services   (United States)

^c Medical Communications Team   (United States)

Author keywords

Burden; Costs; Psoriasis; Psoriatic arthritis; Quality of life

Indexed keywords

ARTICLE; CARDIOVASCULAR DISEASE; CLINICAL FEATURE; COMORBIDITY; COST OF ILLNESS; DISEASE ACTIVITY; GLOBAL HEALTH SYSTEM; HEALTH CARE COST; HEALTH CARE SYSTEM; HEALTH CARE UTILIZATION; HUMAN; MORTALITY; PRODUCTIVITY; PSORIATIC ARTHRITIS; QUALITY OF LIFE;

EID: 78650213940     PISSN: 10521372     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (69)

1. Gelfand JM, Gladman DD, Mease PJ, et al. Epidemiology of psoriatic arthritis in the population of the United States. J Am Acad Dermatol 2005;53(4):573-577. (Pubitemid 41399922)
2. Taylor WJ. Epidemiology of psoriatic arthritis. Curr Opin Rheumatol 2002;14:98-103.
3. Alamanos Y, Voulgari PV, Drosos AA. Incidence and prevalence of psoriatic arthritis: A systematic review. J Rheumatol 2008;35:1354-1358. (Pubitemid 352000783)
4. Yu AP, Tang J, Xie J, et al. Economic burden of psoriasis compared to the general population and stratified by disease severity. Curr Med Res Opin 2009;25(10):2429-2438.
5. Steele T, Pawaskar M, Balkrishnan R, et al. Does cost-effectiveness play a role in clinical trials? Dermatol Ther 2007;20(2):110-119. (Pubitemid 46817426)
6. Huscher D, Merkesdal S, Thiele K, et al. Cost of illness in rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis, and systemic lupus erythematosus in Germany. Ann Rheum Dis 2006;65(9):1175-1183. (Pubitemid 44277392)
7. de Korte J, Sprangers MA, Mombers FM, Bos JD. Quality of life in patients with psoriasis: A systematic literature review. J Investig Dermatol Symp Proc 2004;9(2):140-147.
8. Donahue KE, Gartlehner G, Jonas DE, et al. Comparative effectiveness of drug therapy for rheumatoid arthritis and psoriatic arthritis in adults. Comparative Effectiveness Review No. 11. Prepared by Research Triangle Institute-University of North Carolina Evidence-Based Practice Center, under Contract No. 290-02-0016. Rockville, Md.: Agency for Healthcare Research and Quality, November 2007. Available at: www.effectivehealth care.ahrq.gov/reports/ final.cfm.
9. Enbrel (etanercept), package insert. Thousand Oaks, Calif.: Amgen; 2008.
10. Remicade (infliximab), package insert. Malvern, Pa.: Centocor OrthoBiotech, Inc.; 2008.
11. Humira (adalimumab), package insert. North Chicago, Ill.: Abbott; 2008.
12. Krueger GG. Clinical features of psoriatic arthritis. Am J Manag Care 2002;8:S160-S170.
13. Gladman DD, Antoni C, Mease P, et al. Psoriatic arthritis: Epidemiology, clinical features, course, and outcome. Ann Rheum Dis 2005;64(Suppl 2):ii14-ii17.
14. Fisher VS. Clinical monograph for drug formulary review: Systemic agents for psoriasis/psoriatic arthritis. J Manag Care Pharm 2005;11(1):33-55.
15. Gladman DD. Clinical, radiological, and functional assessment in psoriatic arthritis: Is it different from other inflammatory joint diseases? Ann Rheum Dis 2006;65(Suppl III):iii22-iii24.
16. Gottlieb A, Korman NJ, Gordon KB, et al. Guidelines of care for the management of psoriasis and psoriatic arthritis, Section 2. J Am Acad Dermatol 2008;58:851-864.
17. McHugh N, Balachrishnan C, Jones SM. Progression of peripheral joint disease in psoriatic arthritis: A 5-year prospective study. Rheumatology 2003;42:778-783. (Pubitemid 37220911)
18. Kavanaugh A, Fransen J. Defining remission in psoriatic arthritis. Clin Exp Rheumatol 2006;24(Suppl 43):S83-S87.
19. Husted JA, Tom BD, Farewell VT, et al. A longitudinal study of the effect of disease activity and clinical damage on physical function over the course of psoriatic arthritis: Does the effect change over time? Arthritis Rheum 2007;56(3):840-849.
20. Husted JA, Tom BD, Farewell VT, et al. Description and prediction of physical functional disability in psoriatic arthritis: A longitudinal analysis using a Markov model approach. Arthritis Rheum 2005;53(3):404-409.
21. Williamson L, Dalbeth N, Dockerty JL, et al. Extended report: Nail disease in psoriatic arthritis - clinically important, potentially treatable, and often overlooked. Rheumatology (Oxford) 2004;43(6):790-794. (Pubitemid 38807439)
22. Salaffi F, Carotti M, Gasparini S, et al. The health-related quality of life in rheumatoid arthritis, ankylosing spondylitis, and psoriatic arthritis: A comparison with a selected sample of healthy people. Health Qual Life Outcomes 2009;7:25.
23. Ritchlin C. Psoriatic disease - from skin to bone. Natl Clin Pract Rheumatol 2007;3(12):698-706.
24. Schatteman L, Mielants H, Veys EM. Gut inflammation in psoriatic arthritis: A prospective ileocolonoscopic study. J Rheumatol 1995;22:680-683.
25. Williamson L, Dockerty JL, Dalbeth N, Wordsworth P. Gastrointestinal disease and psoriatic arthritis. J Rheum 2004;31(7):1469.
26. Rohekar S, Tom BD, Hassa A, et al. Prevalence of malignancy in psoriatic arthritis. Arthritis Rheum 2008;58(1):82-87.
27. Menter A, Gottlieb A, Feldman SR, et al. Guidelines of care for the management of psoriasis and psoriatic arthritis, Section 1. Overview of psoriasis and guidelines of care for the treatment of psoriasis with biologics. J Am Acad Dermatol 2008;58(5):826-850. (Pubitemid 351509656)
28. Nannini C, Cantini F, Niccoli L, et al. Single-center series and systematic review of randomized controlled trials of malignancies in patients with rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis receiving anti-tumor necrosis factor-alpha therapy: Is there a need for more comprehensive screening procedures? Arthritis Rheum 2009;61(6):801-812.
29. Han C, Robinson DW Jr, Hackett MV, et al. Cardiovascular disease and risk factors in patients with rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis. J Rheumatol 2006;33(11):2167-2172.
30. Gladman DD, Ang M, Su L, et al. Cardiovascular morbidity in psoriatic arthritis. Ann Rheum Dis 2009;68(7):1131-1135.
31. Agarwal S, Gullick N, Macedo A, et al. 10-year cardiovascular risk in patients with psoriatic arthritis (Abstract 611). Presented at the 71st annual scientific meeting of the American College of Rheumatology, Boston, November 11-16, 2007.
32. Tam LS, Shang Q, Li EK, et al. Subclinical carotid atherosclerosis in patients with psoriatic arthritis. Arthritis Rheum 2008;59(9):1322-1331.
33. Tam LS, Tomlinson B, Chu TT-W, et al. Cardiovascular risk profile of patients with psoriatic arthritis compared to controls: The role of inflammation. Rheumatology (Oxford) 2008;47(5):718-723.
34. Gonzalez-Juanatey C, Amigo-Diaz E, Miranda-Filloy JA, et al. Lack of echocardiographic and Doppler abnormalities in psoriatic arthritis patients without clinically evident cardiovascular disease or classic atherosclerosis risk factors. Semin Arthritis Rheum 2006;35(5):333-339.
35. Gonzalez-Juanatey C, Llorca J, Amigo-Diaz E, et al. High prevalence of subclinical atherosclerosis in psoriatic arthritis patients without clinically evident cardiovascular disease or classic atherosclerosis risk factors. Arthritis Rheum 2007;57(6):1074-1080. (Pubitemid 47237336)
36. Gonzalez-Juanatey C, Llorca J, Miranda-Filloy JA, et al. Endothelial dysfunction in psoriatic arthritis patients without clinically evident cardiovascular disease or classic atherosclerosis risk factors. Arthritis Rheum 2007;57(2):287-293. (Pubitemid 47164092)
37. Kimhi O, Caspi D, Bornstein NM, et al. Prevalence and risk factors of atherosclerosis in patients with psoriatic arthritis. Semin Arthritis Rheum 2007;36(4):203-209.
38. Borman P, Toy GG, Babaoglu S, et al. A comparative evaluation of quality of life and life satisfaction in patients with psoriatic and rheumatoid arthritis. Clin Rheumatol 2007;26(3):330-334. (Pubitemid 46486962)
39. Mease PJ. Assessing the impact of psoriatic arthritis on patient function and quality of life: Lessons learned from other rheumatologic conditions. Semin Arthritis Rheum 2009;38(4):320-335.
40. Husted JA, Gladman DD, Farewell VT, Cook RJ. Health-related quality of life of patients with psoriatic arthritis: A comparison with patients with rheumatoid arthritis. Arthritis Rheum 2001;45(2):151-158. (Pubitemid 32954441)
41. Sokoll KB, Helliwell PS. Comparison of disability and quality of life in rheumatoid and psoriatic arthritis. J Rheumatol 2001;28(8):1842-1846. (Pubitemid 32726931)
42. Callis DK, Wong B, Horn EJ, Krueger GG. Psoriatic arthritis is a strong predictor of sleep interference in patients with psoriasis. J Am Acad Dermatol 2009;60(4):604-608.
43. Husted JA, Tom BD, Schentag CT, et al. Occurrence and correlates of fatigue in psoriatic arthritis (PsA). Ann Rheum Dis 2009;68(10):1553-1558.
44. Khraishi MM, Longo N, Pellegrino A, Sampalis JS. The prevalence of co-morbidities in a psoriatic arthritis cohort (Abstract 514). Presented at the 73rd annual scientific meeting of the American College of Rheumatology, Philadelphia, October 17-21, 2009.
45. Hu SW, Holt EW, Husni ME, Qureshi AA. Willingness-to-pay stated preferences for 8 health-related quality-of-life domains in psoriatic arthritis: A pilot study. Semin Arthritis Rheum 2010;39(5):384-397.
46. Zink A, Thiele K, Huscher D, et al. Healthcare and burden of disease in psoriatic arthritis: A comparison with rheumatoid arthritis and ankylosing spondylitis. J Rheumatol 2006;33(1):86-90.
47. Williams JP, Meyers JA. Immune-mediated inflammatory disorders (I.M.I.D.s): The economic and clinical costs. Am J Manag Care 2002;8:S664-S681.
48. Brodszky V, Balint P, Geher P, et al. Disease burden of psoriatic arthritis compared to rheumatoid arthritis, Hungarian experiment. Rheumatol Int 2009;30(2):199-205.
49. Javitz HS, Ward MM, Farber E, et al. The direct cost of care for psoriasis and psoriatic arthritis in the United States. J Am Acad Dermatol 2002;46(6):850-860.
50. Verstappen SM, Watson KD, McGrother K, et al. Working status in the BSR Biologics Register (Abstract 798). Presented at the 72nd annual scientific meeting of the American College of Rheumatology, San Francisco, October 24-28, 2008. Rheumatol (Oxford) 2010;49(8):1570-1577.
51. Mau W, Listing J, Huscher D, et al. Employment across chronic inflammatory rheumatic diseases and comparison with the general population. J Rheumatol 2005;32(4):721-728.
52. Fernandez-Sueiro JL, Willisch A, Pertega S, et al. Factors associated to employment in ankylosing spondylitis and psoriatic arthritis (Abstract 596). Presented at the 71st annual scientific meeting of the American College of Rheumatology, Boston, November 11-16, 2007.
53. Fernandez-Sueiro JL, Willisch A, Pertega S, et al. Burden of anky-losing spondylitis and psoriatic arthritis on work capability, physical function, and quality of life (Abstract 1187). Presented at the 71st annual scientific meeting of the American College of Rheumatology, Boston, November 11-16, 2007.
54. Wallenius M, Skomsvoll JF, Koldingsnes W, et al. Work disability and health-related quality of life in males and females with psoriatic arthritis. Ann Rheum Dis 2009;68(5):685-689.
55. Ali Y, Tom BD, Schentag CT, et al. Improved survival in psoriatic arthritis with calendar time. Arthritis Rheum 2007;56(8):2708-2714. (Pubitemid 47237289)
56. Borman P, Babaoglu S, Gur G, et al. Bone mineral density and bone turnover in patients with psoriatic arthritis. Clin Rheumatol 2008;27(4):443-447. (Pubitemid 351404298)
57. Chandran V, Bhella S, Schentag C, Gladman DD. Functional assessment of chronic illness therapy-fatigue scale is valid in patients with psoriatic arthritis. Ann Rheum Dis 2007;66(7):936-939. (Pubitemid 46999797)
58. Frediani B, Allegri A, Falsetti P, et al. Bone mineral density in patients with psoriatic arthritis. J Rheumatol 2001;28(1):138-143.
59. Gladman DD, Farewell VT, Wong K, Husted J. Mortality studies in psoriatic arthritis: Results from a single outpatient center: II. Prognostic indicators for death. Arthritis Rheum 1998;41(6):1103-1110.
60. Lindqvist UR, Alenius GM, Husmark T, et al. The Swedish early psoriatic arthritis register - 2-year follow-up: A comparison with early rheumatoid arthritis. J Rheumatol 2008;35(4):668-673.
61. Long JA, Husted JA, Gladman DD, Farewell VT. The relationship between patient satisfaction with health and clinical measures of function and disease status in patients with psoriatic arthritis. J Rheumatol 2000;27(4):958-966.
62. Mease P, Ganguly R, Wanke L, et al. How much improvement in functional status is considered important by patients with active psoriatic arthritis: Applying the Outcome Measures in Rheumatoid Arthritis Clinical Trials (OMERACT) Group guidelines (Abstract SAT0015). Presented at 5th annual European League Against Rheumatism (EULAR) Congress, Berlin, Germany, June 9-12, 2004. Ann Rheum Dis 2004;63:39.
63. Radtke MA, Reich K, Blome C, et al. Prevalence and clinical features of psoriatic arthritis and joint complaints in 2009 patients with psoriasis: Results of a German national survey. J Eur Acad Dermatol Venereol 2009;23(6):683-691.
64. Taccari E, Spadaro A, Rinaldi T, et al. Comparison of the Health Assessment Questionnaire and Arthritis Impact Measurement Scale in patients with psoriatic arthritis. Rev Rhum Engl Ed 1998;65(12):751-758. (Pubitemid 29030654)
65. Gibbs A, Veale D, Fitzgerald O, Bresnihan B. Health-related quality of life in patients with psoriatic arthritis and ankylosing spondylitis: A comparison with rheumatoid arthritis (Abstract THU0543). Ann Rheum Dis 2006;65(Suppl II):280.
66. Foundation for Managed Care Pharmacy/Academy of Managed Care Pharmacy (FMCP). The AMCP Format for Formulary Submissions (Version 3.0). A Format for Submission of Clinical and Economic Data in Support of Formulary Consideration by Health Care Systems in the United States. Alexandria, Va.: Academy of Managed Care Pharmacy; October 2009. Available at: www.fm cpnet.org. Accessed April 22, 2010.
67. WellPoint. Health Technology Assessment Guidelines: Drug Submission Guidelines for Re-evaluation of Products, Indications, and Formulations. Updated September 2008. Available at: https://www.wellpointnextrx.com/shared/ noapplication/f1/s0/t0/pw-ad080614.pdf. Accessed April 22, 2010.
68. National Institute for Clinical Excellence (NICE). Guide to the Methods of Technology Appraisal (reference N0515). National Health Services. Available at: www.nice.org.uk/aboutnice/howwework/devnicetech/ technologyappraisalprocessguides/guide-to-the-methods-of-technology-appraisal- reference-n0515.jsp. Accessed April 22, 2010.
69. Scottish Medicines Consortium. New Product Assessment Form. Available at: www.scottishmedicines.org.uk/smc/22.html. Accessed April 22, 2010.